Tag
A new continuous index—EASE‑CD—focuses on ulcer presence, size, depth and proportion of ulcerated surface; it is reliable, responsive, and externally validated across two RCT datasets, offering a practical endoscopic endpoint for trials and
Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.
Phase 3 studies demonstrate guselkumab’s efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn’s disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.
The EASE-CD index offers a reliable, validated, and responsive tool for quantifying Crohn’s disease ulcer activity in clinical trials and practice, improving upon prior endoscopic indices.
Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.
